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ABSTRACT: The second extracellular loop (ECL2) of the G pro-
tein-coupled receptor (GPCR) family is important for ligand-inter-
action and drug discovery. ECL2 of the family B cardioprotective 
calcitonin gene related peptide (CGRP) receptor is required for cell 
signalling. Family B GPCR ligands have two regions; the N-termi-
nus mediates receptor activation and the remainder confers high-
affinity binding. Comparing antagonism of CGRP8-37 at a number 
of point mutations of ECL2 of the CGRP receptor, we show that 
the ECL2 potentially facilitates interaction with up to the 18 N-ter-
minal residues of CGRP. This has implications for understanding 
family B GPCR activation and for drug design at the CGRP recep-
tor. 
More than a third of all therapeutic compounds target mem-
bers of the G protein-coupled receptor (GPCR) superfam-
ily. Understanding how ligands bind to GPCRs is therefore 
key to modern molecular pharmacology. The second extra-
cellular loop (ECL2) of the GPCR super-family is the larg-
est and most structurally diverse of the ECLs and is vital 
for ligand binding and activation for almost all of these re-
ceptors [1-3]. Crystal structures of the largest sub-family of 
GPCRs (family A) show ECL2 in a variety of confor-
mations, including beta-sheets, alpha helices and unstruc-
tured loops [4-6]. Family B GPCRs includes a smaller 
group of pharmaceutically important peptide-binding re-
ceptors. Conversely, the three available crystal structures of 
family B GPCRs suggest that ECL2 has no significant sec-
ondary structural components [7-9]. Despite this, every bio-
chemical analysis done on the family B GPCR ECL2 re-
gions have found it to be vital for the binding of the respec-
tive peptide ligands and the subsequent activation of vari-
ous signalling pathways [10-12].  
 
Family B GPCRs are all activated by relatively small pep-
tide ligands (typically under 100 amino acids long). They 
have a diverse range of physiological effects (such as cardi-
oprotection, bone resorption, migraine, digestion control, 
glucose homeostasis and steroid hormone responses), 
which has made them of considerable therapeutic interest 
[13]. These peptide ligands are thought to follow a broadly 
consistent binding mechanism, termed the two-domain 
model [14]. Briefly, the C-terminus of the ligand binds to 
the large extracellular N-terminus of its GPCR. This facili-
tates the binding of the N-terminus of the ligand to the ECL 
regions and transmembrane (TM) domain of the receptor. 
This in turn causes receptor activation and second messen-
ger signalling. It is not known exactly where the ligand N-
terminus binds or how that interaction results in the confor-
mational changes that stabilise receptor activation. This in-
formation is needed for our understanding of ligand-bind-
ing and to provide a platform for the design of specific 
molecules for individual receptor structures. 
 
One important member of the family B GPCRs is the 
CGRP receptor. This belongs to the calcitonin-like sub-
family and is of considerable therapeutic interest due to the 
highly potent vasodilatory properties of the CGRP neuro-
peptide ligand. CGRP has cardioprotective properties of 
potential beneficial use in heart failure and hypertension 
[15, 16] and has been implicated in the induction of mi-
graine [17]. The CGRP receptor has also been studied ex-
tensively because of another unusual feature; it functions as 
an obligate heterodimer formed by a GPCR subunit (calci-
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tonin receptor-like receptor; CLR) and a single TM span-
ning protein called receptor activity modifying protein 1 
(RAMP 1) [18].  
 
In our recent alanine scan of the CGRP receptor, we substi-
tuted 24 residues of the ECL2 region and found that 14 had 
significant differences in receptor signalling [12]. The larg-
est differences occurred with mutation of residues in the N-
terminal half of the loop, although the supporting in silico 
modelling data predicted the involvement of C-terminal 
residues in receptor-ligand interactions. This alanine-sub-
stitution analysis identified residues required for CGRP re-
ceptor function providing a platform for a more mechanis-
tic analysis of ECL2. In the present study, six key residues 
identified from the alanine scan of the CGRP receptor were 
selected to investigate the affinity of a truncated version of 
CGRP missing the first seven residues (CGRP8-37). CGRP8-
37 acts as a reversible, competitive antagonist with an affin-
ity approximately 10-fold lower than full length CGRP. It 
is thought that CGRP adheres to the two-domain binding 
model whereby the 8-37 region of CGRP has a discrete 
binding region that facilitates a second binding event al-
lowing the first seven residues of CGRP to act as the acti-
vation domain [14]. 
 
Specifically, we are asking whether the ability of CGRP8-37 
to antagonise a mutant receptor (where the interaction with 
the full length CGRP agonist is impaired) is reduced to the 
same degree as the potency of CGRP. If this is the case, 
then it would imply that the mutated residue interacted with 
both CGRP and CGRP8-37. By contrast, if reduction is just 
limited to CGRP, it follows that the mutated residue is in-
teracting with only the first seven residues of CGRP (either 
directly or by affecting a CGRP-independent activation 
process of the receptor). As labelled CGRP8-37 is not readily 
available to allow a direct measure of its affinity, this is as-
sessed indirectly by looking at the shift the antagonist 
causes in the concentration-response curve to CGRP. If the 
same parallel rightward shift is observed in both WT and 
mutant receptors, then the affinity and mode of antagonism 
is also the same. 
 
For this study, we have targeted receptor mutations that ei-
ther had the biggest reduction in cAMP signalling (R274A, 
D280A and W283A) or those that were predicted to make 
ligand contacts in our earlier study (I284A, D287A and 
T288A) [12]. 
 
The binding affinity, expressed as -Log Kd (pKd) for 
CGRP8-37 to the WT and mutant receptors was estimated ei-
ther by the shift in the dose ratio where there was no signif-
icant change in maximum response (Emax) in the presence 
of the antagonist (pKd = (-Log([CGRP8-37]/Dose-ratio -1) 
or by the method of Gaddum where the Emax was de-
pressed [19]. Cos 7 cells were transiently transfected with 
the WT or mutant receptor construct in a mammalian ex-
pression vector pcDNA3.1- (Invitrogen, UK) and co-trans-
fected with a pcDNA3/RAMP1 construct as described pre-
viously [12]. Cells were stimulated with CGRP agonist 
(over a concentration range of 10-12 M to 10-5 M) in the 
presence or absence of 10-7 M CGRP8-37 antagonist and 
cAMP was measured using the FRET-based Lance-assay as 
described [20]. Isobutyl methyl xanthine (IBMX) was nor-
mally present at 1mM to prevent cAMP breakdown except 
for kinetic experiments. 10-7 M CGRP8-37 was used as lower 
concentrations of CGRP8-37 gave CGRP activation curves 
that were poorly resolved from the control in the absence of 
antagonist; higher concentrations gave incomplete curves 
(data not shown).  
 
Homology models of the active CLR were generated using 
Modeller [21] utilising the recently solved cryo-EM struc-
tures of the activated Glucagon-like peptide-1 receptor and 
calcitonin receptor (PDB 5VAI and 5UZ7, respectively) 
[22, 23]. 1000 models were generated which were subse-
quently refined and ranked using the membrane relax mod-
ule of Rosetta [24]. The best model was chosen based on 
the Rosetta membrane scoring function [24]. 
 
The signalling curves for this study are shown in figure 1. 
The Emax values of the alanine substitution receptor (+ 
CGRP8-37) were compared to a normalised alanine substitu-
tion receptor – CGRP8-37 (set to 100%) and compared using 
a one sample t test (table 1 and figure 2). The computed 
pKd values are shown in table 1. 
 
I284A resulted in a significant reduction in the affinity of 
CGRP8-37 (table 1). It is likely therefore that the reduction in 
cAMP signalling observed with the I284A mutant [12] is 
caused by a disruption of the receptor’s ability to interact 
with the CGRP 8-37 region. There was also a reduction in 
the affinity for W283A. Conversely, the shift in the CGRP 
concentration-response curve caused by the CGRP8-37 antag-
onist at the R274A, D280A, and T288A receptors was not 
significantly different to that seen for the WT CGRP recep-
tor. This suggests that the deleterious effects on signalling of 
these mutants previously seen [12] is not mediated by the 
CGRP 8-37 region and therefore, stabilises direct or indirect 
interactions between the CGRP receptor and the first seven 
residues of CGRP (the activation domain). However, for all 
of these mutants as well as W283A, CGRP8-37 appeared to 
act non-competitively at the mutants, with significant reduc-
tions in Emax (Figure 2). D287A had no significant effect 
on CGRP potency, in contrast to our previous study where 
there was a 7.6-fold reduction in potency [12]. This may re-
flect cell line variability. 
The apparent change in mode of antagonism is unexpected. 
Caution is needed with this interpretation, as it was not pos-
sible to construct full concentration-response curves to 
CGRP in the presence of CGRP8-37 for the mutants with 
lower CGRP potency, as the required concentrations of 
CGRP would be impractical. However, when we fit “ex-
pected” concentration-response curves in accordance with 
competitive inhibition assuming a full Emax (dotted line 
graphs in figure 1), then the shift in the curve for CGRP for 
the mutant receptors would be even greater than for the WT 
receptors; i.e. the affinity for CGRP8-37 would have in-
creased. In either interpretation, these mutations give unex-
pected effects. 
Commented [MW1]: Is this wording definitely correct? I found 
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There was no evidence of any non-competitive inhibition by 
CGRP8-37 on the WT receptor, even when cells were trans-
fected with only 10% of the normal CLR/RAMP1 cDNA 
(data not shown). Under these conditions, any receptor re-
serve will have been removed (the maximum stimulation of 
cAMP was reduced by 93%), which might otherwise mask 
non-competitive behaviour of antagonists. There was still a 
clear shift of the CGRP concentration response curve in the 
presence of 10-7 M CGRP8-37 (shift 1.54 ± 0.35, n=3), but 
there was no significant change in the Emax in the presence 
of the antagonist (125 ± 25% of CGRP alone). 
Of the residues examined in this study, only I284 is pre-
dicted to face bound CGRP in a model of CLR (figure 3); 
interestingly it interacts with the 8-18 helix of the peptide. 
T288 may have a weak interaction with the extreme N-ter-
minus of CGRP, but the other residues face into the binding 
pocket. The model is consistent with cryo-electron micro-
scope structures showing the binding of calcitonin and 
GLP-1 to their receptors [22, 23]. In the GLP-1 receptor 
(5VAI at the Protein Structure Databank) the equivalent of 
I284, T298, is adjacent to S18 of GLP-1. The model sug-
gests it is unlikely that any part of ECL2 interacts with the 
extracellular domain of CLR of RAMP1, unless the signal 
peptide of CLR is not cleaved. We speculate that the R274, 
D280 and W283 and (to a lesser extent) T288 are important 
for maintaining the architecture of the peptide-binding 
pocket. In support of this, there is a correlation between the 
reduction in CGRP potency at the mutants and the decrease 
in Emax in the presence of CGRP8-37 (figure 2b). We sug-
gest that when R274, D280 and W283 and T288 are mu-
tated, residues 1-7 of CGRP no longer fit easily into this 
pocket, whereas CGRP8-37 binds relatively unimpaired. To 
test this, we investigated the time course of cAMP produc-
tion by CGRP at W283A in the absence of IBMX, nor-
mally present in our assays to prevent cAMP breakdown. 
This confirmed that the kinetics of receptor activation was 
much slower in this mutant compared to WT, consistent 
with a reduction in the association rate of binding of 
CGRP. By contrast the kinetics of CGRP at I284A are the 
same as WT (figure 2c).  
 
This work is the first mutational evidence to map the inter-
action of CGRP within ECL2 of its receptor. The data sug-
gests that the mode of interaction of CGRP8-37 with the 
CGRP receptor is likely to be more complicated than pre-
dicted from a simple consideration of the two-domain 
model [14] where residues 1-7 are considered to be the sole 
determinant of agonist activity. In a previous structure-ac-
tivity study, we demonstrated that mutations to residues 8 
and 9 of CGRP gave partial agonists, challenging a simplis-
tic notion that CGRP1-7 is the sole determinant of receptor 
activity [25]. This is further supported by a study on the al-
lied calcitonin receptor, where CGRP8-37 is a partial agonist 
at the complex between this receptor and RAMP1 [26].  
The current data suggests that a number of residues of 
CGRP beyond the first seven interact in the vicinity of 
ECL2 and so could directly influence the TM bundle. This 
helps our understanding of receptor activation as well as 
emphasising the key role of ECL2 in the CGRP receptor. 
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Figure 1. Concentration-response curves to CGRP of Cos7 cells 
transfected with WT CGRP receptor (WT CLR + R1) or alanine 
substitution receptor (mutant CLR + R1). Cells were stimulated 
with CGRP in either the presence (open circles) or absence (closed 
circles) of 10-7 M CGRP8-37. Raw cAMP values were normalized to 
WT (in the absence of CGRP8-37) basal and Emax values. The 
curves show means ± s.e.m values of 3-5 determinations. The bro-
ken lines in the graphs of the mutant receptors show the fit if it is 
assumed that the maximum response is unchanged in the presence 
of CGRP8-37. 
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Figure 2a. % Emax values of mutants in the presence of CGRP8-37 
relative to Emax values without antagonist. Values are means ± 
s.e.m. of 3-7 determinations. Significant differences compared to 
100 were determined using a one sample t test, * p value < 0.05. b) 
Correlation between pEC50 for CGRP and change in Emax at ala-
nine mutants. c) Time course of cAMP production in response to 
CGRP at WT, W283A and I284A receptors. Points are means ± 
s.e.m. of 3 determinations.  
 
Figure 3. Model of CGRP (green) bound to CLR (yellow) and 
RAMP1 (blue), showing key residues in ECL2 of CLR.  
 
 
 
 
Table 1. Estimated pKd values for CGRP8-37 at WT and mutant 
CGRP receptors 
 
 
 
 
 
 
 
 
 
 
 
 
Values are means ± s.e.m. *** p value < 0.001 versus WT (un-
paired Student’s t-test). 
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CLR Mutant pKd WT pKd mutant n 
R274A 8.64±0.10 8.40±0.05 4 
D280A 8.41±0.01 8.43±0.15 4 
W283A 8.67±0.07 7. 51±0.19*** 7 
I284A 8.77±0.09 7.85±0.12*** 4 
D287A 8.79±0.33 8.65±0.35 3 
T288A 8.54±0.18 8.87±0.21 4 
 5 
 
Notes 
The authors declare no competing financial interests. 
ACKNOWLEDGMENT  
We thank Chris Reynolds for useful discussions. 
ABBREVIATIONS 
(Word Style "Section_Content"). CLR, calcitonin receptor-like re-
ceptor; CGRP, calcitonin gene related peptide; ECL, extracellular 
loop GPCR, G protein-coupled receptor; TM. transmembrane; WT, 
wild-type.  
REFERENCES 
1. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. 
(2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Sci-
ence 289: 739-745. 
2. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, et 
al. (2007) High-resolution crystal structure of an engineered human beta2-
adrenergic G protein-coupled receptor. Science 318: 1258-1265. 
3. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, et al. (2010) Structure 
of the human dopamine D3 receptor in complex with a D2/D3 selective 
antagonist. Science 330: 1091-1095. 
4. Wu H, Wacker D, Mileni M, Katritch V, Han GW, et al. (2012) Structure 
of the human kappa-opioid receptor in complex with JDTic. Nature 485: 
327-332. 
5. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, et al. 
(2012) Structure of the human M2 muscarinic acetylcholine receptor bound 
to an antagonist. Nature 482: 547-551. 
6. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards 
PC, et al. (2008) Structure of a beta1-adrenergic G-protein-coupled recep-
tor. Nature 454: 486-491. 
7. Hollenstein K, Kean J, Bortolato A, Cheng RK, Dore AS, et al. (2013) 
Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 
499: 438-443. 
8. Siu FY, He M, de Graaf C, Han GW, Yang D, et al. (2013) Structure of 
the human glucagon class B G-protein-coupled receptor. Nature 499: 444-
449. 
9. Jazayeri A, Dore AS, Lamb D, Krishnamurthy H, Southall SM, et al. 
(2016) Extra-helical binding site of a glucagon receptor antagonist. Nature 
533: 274-277. 
10. Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, et al. (2012) 
Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-
1R) has a critical role in GLP-1 peptide binding and receptor activation. J 
Biol Chem 287: 3642-3658. 
11. Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, et al. 
(2009) Alanine scanning mutagenesis of the second extracellular loop of 
type 1 corticotropin-releasing factor receptor revealed residues critical for 
peptide binding. Mol Pharmacol 75: 793-800. 
12. Woolley MJ, Watkins HA, Taddese B, Karakullukcu ZG, Barwell J, et 
al. (2013) The role of ECL2 in CGRP receptor activation: a combined mod-
elling and experimental approach. J R Soc Interface 10: 20130589. 
13. Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, et al. 
(2014) Insights into the structure of class B GPCRs. Trends Pharmacol Sci 
35: 12-22. 
14. Hoare SR (2005) Mechanisms of peptide and nonpeptide ligand binding 
to Class B G-protein-coupled receptors. Drug Discov Today 10: 417-427. 
15. Brain SD, Grant AD (2004) Vascular actions of calcitonin gene-related 
peptide and adrenomedullin. Physiol Rev 84: 903-934. 
16. Smillie SJ, Brain SD (2011) Calcitonin gene-related peptide (CGRP) 
and its role in hypertension. Neuropeptides 45: 93-104. 
17. Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin 
gene-related peptide: physiology and pathophysiology. Physiol Rev 94: 
1099-1142. 
18. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, et al. (1998) 
RAMPs regulate the transport and ligand specificity of the calcitonin-recep-
tor-like receptor. Nature 393: 333-339. 
19. Kenakin TP (2014) A Pharmacology Primer: Techniques for more ef-
fective and strategic drug discovery (4th Edition): Academic Press, Elsevier. 
Section 6.4. 
20. Hunter MR, Glass M (2015) Increasing the flexibility of the LANCE 
cAMP detection kit. J Pharmacol Toxicol Methods 71: 42-45. 
21. Hay DL, Harris PW, Kowalczyk R, Brimble MA, Rathbone DL, et al. 
(2014) Structure-activity relationships of the N-terminus of calcitonin gene-
related peptide: key roles of alanine-5 and threonine-6 in receptor activa-
tion. Br J Pharmacol 171: 415-426. 
 
  
6 
Authors are required to submit a graphic entry for the Table of Contents (TOC) that, in conjunction with the manuscript title, 
should give the reader a representative idea of one of the following: A key structure, reaction, equation, concept, or theorem, 
etc., that is discussed in the manuscript. Consult the journal’s Instructions for Authors for TOC graphic specifications. 
 
 
